Inclusion criteria: Locally advanced or metastatic cancer patients for who that standard treatment is invalid, unavailable or intolerable. Enrollment will be restricted to participants with evidence of a RET gene alteration.
Sponsor/Collaborator: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Contact and Locations:
Study contact: Shun Lu, MD.
Phone Number: 13601813062
Email: shun_lu@hotmail.com
Mechanism of action: Small molecular, oral potent, selective RET inhibitor
Phases: Phase 1
NCT Number: NCT05207787
Status: Recruiting
